Immix Biopharma (NASDAQ:IMMX) Stock: Insider Gabriel Morris Acquires 1,418 Shares

Immix Biopharma logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CFO Gabriel Morris bought 1,418 shares at an average price of $7.06, spending about $10,011. He now directly owns 292,847 shares, a 0.49% increase in his position.
  • Immix Biopharma reported quarterly EPS of -$0.19, in line with analyst expectations. The stock opened at $7.04, below its 50- and 200-day moving averages.
  • Analysts have a consensus “Moderate Buy” rating and an average price target of $24.14; eight rate the stock Buy and one Sell. Immix is a clinical-stage biotech developing cell therapies, including investigational CAR T candidate NXC-201.
  • MarketBeat previews top five stocks to own in December.

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) CFO Gabriel Morris purchased 1,418 shares of Immix Biopharma stock in a transaction dated Wednesday, November 18th. The shares were acquired at an average cost of $7.06 per share, for a total transaction of $10,011.08. Following the transaction, the chief financial officer directly owned 292,847 shares of the company's stock, valued at approximately $2,067,499.82. This represents a 0.49% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Immix Biopharma Stock Performance

Shares of IMMX stock opened at $7.04 on Friday. The stock has a market capitalization of $590.02 million, a P/E ratio of -8.48 and a beta of 0.29. Immix Biopharma, Inc. has a fifty-two week low of $3.78 and a fifty-two week high of $15.10. The company has a 50 day moving average price of $9.35 and a 200 day moving average price of $9.61.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.19). On average, research analysts forecast that Immix Biopharma, Inc. will post -0.75 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on IMMX shares. Morgan Stanley boosted their price objective on shares of Immix Biopharma from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Wednesday. Citigroup reiterated a "market outperform" rating on shares of Immix Biopharma in a report on Wednesday, September 30th. Mizuho decreased their target price on Immix Biopharma from $23.00 to $22.00 and set an "outperform" rating for the company in a research report on Wednesday. HC Wainwright lifted their target price on Immix Biopharma from $25.00 to $27.00 and gave the stock a "buy" rating in a report on Monday. Finally, Needham & Company LLC upped their target price on Immix Biopharma from $21.00 to $30.00 and gave the company a "buy" rating in a report on Tuesday, September 29th. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $24.14.

Check Out Our Latest Stock Analysis on IMMX

Hedge Funds Weigh In On Immix Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the business. Jupiter Topco LLC bought a new position in shares of Immix Biopharma during the second quarter valued at $100,816,000. Janus Henderson Group PLC increased its position in shares of Immix Biopharma by 22.5% during the 1st quarter. Janus Henderson Group PLC now owns 4,802,002 shares of the company's stock worth $43,698,000 after purchasing an additional 880,434 shares in the last quarter. BlackRock Inc. bought a new position in Immix Biopharma during the 2nd quarter valued at about $30,827,000. Opaleye Management Inc. acquired a new position in Immix Biopharma in the second quarter valued at about $24,177,000. Finally, Marshall Wace LLP boosted its position in Immix Biopharma by 3.3% in the third quarter. Marshall Wace LLP now owns 1,854,215 shares of the company's stock valued at $19,284,000 after buying an additional 59,307 shares in the last quarter. 11.26% of the stock is owned by institutional investors.

Immix Biopharma Company Profile

(Get Free Report)

Immix Biopharma is a clinical-stage biopharmaceutical company developing cell therapies for serious diseases, with a focus on relapsed or refractory AL amyloidosis, a rare condition in which abnormal proteins build up in organs and tissues. The company's lead candidate, NXC-201, is an investigational CAR T-cell therapy designed to target BCMA, a protein found on certain plasma cells. It is being studied in clinical trials and has not been approved for commercial use. Immix Biopharma is based in the United States and is led by Chief Executive Officer Ilya Rachman.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Immix Biopharma Right Now?

Before you consider Immix Biopharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.

While Immix Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines